Hematologic depression following therapy with strontium-89 chloride.
Initial clinical trials using strontium-89 (Sr-89) chloride for the treatment of painful skeletal metastases have observed minimal or no hematological depression secondary to the radiostrontium. A patient with marked bone marrow depression temporally related to the administration of the Sr-89 is reported, and the need for close hematological monitoring is emphasized. Bone marrow tumor replacement may predispose patients to marrow depression from radiostrontium, and such patients should be treated with caution.
D000368:Aged; D001853:Bone Marrow / Q000528:radiation effects*; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary*; D006801:Humans; D008297:Male; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D013324:Strontium / Q000627:therapeutic use; D013326:Strontium Radioisotopes / Q000627:therapeutic use*
D013326:Strontium Radioisotopes; C025700:strontium chloride; D013324:Strontium